ClinicalTrials.gg
RecruitingNCT06202261Updated Mar 12, 2024

A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer

A Phase 1/2 interventional study of TQB2930 for injection and Paclitaxel for injection (albumin-bound) in Metastatic Breast Cancer, Recurrent Breast Cancer and Advanced Malignancies, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Recruiting at 2 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-03-12.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Apr 2023, registered Jan 2024).
  • Started Apr 2023; still recruiting 3 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
154
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies in Breast Neoplasms by Sino Biopharmaceutical Limited — 11 open to participants now, 16 under way, 8 of them phase 3. Breast Neoplasms · Sino Biopharmaceutical Limited.

Planned enrollment
13th of 28
154 · median 138
Started
2023
with 4 others
Phase 1/2
5 of 28
2 open now
Primary completion
2026-12
later than 7 of 15 live
Registered
17th of 28
by date

Among the 28 studies in Breast Neoplasms by Sino Biopharmaceutical Limited, this one is the 13th largest by planned enrollment, is one of 5 that started in 2023, is one of 5 in phase 1/2, reaches primary completion later than 7 of the 15 other live ones, and was the 17th registered.

Breast Neoplasms

14,840 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

11 of the 28 studies in Breast Neoplasms by Sino Biopharmaceutical Limited are open now, in 1 country. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Where they have run

Who these studies take

Of the 2,398 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 590 (25%) stop at 75 or younger; 103 take children under 18; 213 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Breast Neoplasms by Sino Biopharmaceutical Limited, or all of them as a file.
02

Study summary

This is a phase Ib/II exploratory study. Phase Ib includes the dose escalation and expansion study of monotherapy, as well as the dose escalation study of combination therapy. After determining the maximum tolerated dose (MTD), a dose expansion study is conducted to observe the safety and efficacy in monotherapy. Phase II study is to further observe the safety and efficacy of TQB2930 combined with albumin-paclitaxel (cohort 3), or chemotherapy selected by investigators (cohort 4).

03

Conditions studied

  • Metastatic Breast Cancer
  • Recurrent Breast Cancer
  • Advanced Malignancies

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age: 18-75 years old; Performance Status (ECOG PS) score: 0\~1; The expected survival is over 3 months.
  • Phase Ib

    1. Advanced confirmed by cytology / histopathology, priority given to subjects with expression or amplification;
    2. Subjects with malignant tumors who have failed standard treatment or lack effective treatment;
    3. Confirmed presence of at least one evaluable lesion according to 1.1 criteria
  • Phase II

    1. Hormone receptor (HR)-negative, HER2-positive breast cancer confirmed by cytology / histopathology, with evidence of local recurrence or distant , unsuitable for surgery or radiotherapy for curative purposes:
    2. Have not received systemic antitumor therapy for metastatic stage; Systemic use of endocrine therapy is permitted, but not exceed 2 lines;
    3. at least one that meets the RECIST 1.1 criteria.
  • Major organs are functioning normally.
  • Female subjects of reproductive age should agree to use methods during the study period and until 6 months after the end of the study; Negative serum pregnancy / urine pregnancy test within 7 days prior to study enrollment and must be non-lactating subjects; Male subjects should agree to use contraception during the study and until six months after the end of the study.

Exclusion criteria

Exclusion Criteria:

  • Have occured other malignant tumors within 3 years prior to first dose.
  • Unalleviated toxicity above (CTCAE) grade 1 due to any prior treatment;
  • Received major surgical treatment, open , or significant traumatic injury within 28 days prior to the first dose;
  • Long-term unhealed wounds or fractures;
  • Arterial/venous thrombosis events occurred within 6 months before the first dose;
  • Have a history of psychotropic drug abuse and can't get rid of it or have mental disorders;
  • Subject with any severe and/or uncontrolled disease;
  • Subjects who have been treated with other antitumor agents such as chemotherapy, radiotherapy, or immunotherapy within 4 weeks prior to the first dose, within 5 half-lives of the drug;
  • Have used traditional chinese medicine with anti-tumor indications approved by National Medical Products Administration (NMPA) within 2 weeks before the first dose;
  • Severe bone injury due to bone ;
  • Subjects with untreated active or meningeal metastases or cancerous meningitis;
  • In the course of previous -targeted therapy, (LVEF) decreased to \<50% or absolute LVEF decreased >15%;
  • Cumulative doses of anthracyclines exceeded doxorubicin or doxorubicin liposomes >360 mg/m2;
  • Uncontrolled hypercalcemia or symptomatic hypercalcemia requires continued bisphosphonate therapy
  • Patients with severe after the use of monoclonal antibodies;
  • Has participated in other antitumor clinical trials within 4 weeks prior to the first dose.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
154 participants (estimated)

Study arms

  • Experimental
    TQB2930 for injection

    TQB2930 for injection,10 mg/kg, quaque week (QW), 21 day as a treatment cycle; TQB2930 for injection, 20 mg/kg, quaque 2 weeks (Q2W), 28 day as a treatment cycle; TQB2930 for injection,30 mg/kg, quaque 3 weeks (Q3W), 21 day as a treatment cycle.

    Drug: TQB2930 for injection

  • Experimental
    TQB2930 for injection 30mg/kg + Paclitaxel for injection (albumin-bound)

    TQB2930 for injection 30mg/kg combined with paclitaxel (albumin-bound) for injection, 21 days for one treatment cycle

    Drug: TQB2930 for injection · Drug: Paclitaxel for injection (albumin-bound)

  • Experimental
    TQB2930 for injection+TQB3616 capsule for injection + fulvestrant injection

    TQB2930 for injection 20mg/kg combined with TQB3616 capsule 120mg or 150mg or 180mg, and fulvestrant injection. Q2W, 28 days a cycle.

    Drug: TQB2930 for injection · Drug: TQB3616 capsule · Drug: Fulvestrant injection

  • Experimental
    TQB2930 for injection + chemotherapy

    TQB2930 for injection 30mg/kg combined with capecitabine tablets or vinorelbine tartrate injection or eribulin mesylate injection or gemcitabine hydrochloride for injection, 21 days a cycle.

    Drug: TQB2930 for injection · Drug: Capecitabine tablets · Drug: Vinorelbine tartrate injection · Drug: Eribulin mesylate injection · Drug: gemcitabine hydrochloride for injection

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum tolerated dose (MTD)

    The highest dose when dose-limiting toxicity (DLT) occurs in less than 33% of subjects.

    Time frame: Baseline up to 4 months

  2. Phase II recommended dose (P2RD)

    Optimal tolerated dose determined after the end of phase 1

    Time frame: Baseline up to 1 year

  3. Investigators assessed Objective remission rate (ORR) based on Response Evaluation Criteria In Solid Tumors (RECIST) 1.1

    The proportion of subjects with complete response (CR) and partial response (PR) whose tumor volume reduced to a predetermined value and maintained the minimum time limit.

    Time frame: Baseline up to 2 year

Secondary outcomes

  1. Immunogenicity

    Incidence of anti-drug antibody (ADA)

    Time frame: Pre-dose on Cycle 1 Day 1, Cycle 2 Day 1, Cycle 4 Day 1, Cycle 7 Day 1, Cycle 12 Day 1, each cycle is 21 or 28 days.

  2. Peak concentration (Cmax), QW

    The maximum serum concentration after administration

    Time frame: Pre-dose, 30 minuets, 4, 8, 24, 48, 72 hours after dose on Cycle 1 Day 1, Cycle 2 Day 1; Pre-dose on Cycle 1 Day 8, Cycle 1 Day 15, Cycle 2 Day 8, each cycle is 21 days.

  3. Peak concentration (Cmax), Q2W

    The maximum serum concentration after administration

    Time frame: Pre-dose, 30 minuets, 4, 8, 24, 48, 72, 168, 240 hours after dose on Cycle 1 Day 1, Cycle 2 Day 1; Pre-dose on Cycle 1 Day 15, Cycle 2 Day 15, each cycle is 28 days.

  4. Peak concentration (Cmax), Q3W

    The maximum serum concentration after administration

    Time frame: Pre-dose, 30 minuets, 4, 8, 24, 48, 72, 168, 240, 336 hours after dose on Cycle 1 Day 1, Cycle 2 Day 1; Pre-dose on Cycle 3 Day 1, each cycle is 21 days.

  5. Overall survival (OS)

    From randomization to the time of death from any cause.

    Time frame: Baseline up to 4 years

  6. Adverse event rate

    The occurrence of all adverse events (AEs), serious adverse events (SAEs) and treatment-related adverse events (TEAEs).

    Time frame: Baseline up to 2 years

  7. Progression-free survival (PFS)

    The time between the first medication and disease progression (PD) or death before PD.

    Time frame: Baseline up to 1 year

  8. Disease control rate (DCR)

    The ratio of disease control cases (partial remission, complete response, stable disease) to total cases.

    Time frame: Baseline up to 2 years

  9. Duration of remission (DOR)

    The time from the first evaluation of the tumor as a complete or partial response to the first evaluation as tumor progression or death.

    Time frame: Baseline up to 2 years

  10. Clinical benefit rate (CBR)

    The ratio of disease control cases (partial remission, complete response, stable disease ≥ 6 month) to total cases.

    Time frame: Baseline up to 2 years

  11. Peak concentration (Cmax), arm 2

    The maximum serum concentration after administration in arm 2

    Time frame: Pre-dose, 30 minuets after dose of Cycle 1 Day 1,Cycle 2 Day 1, Cycle 4 Day 1,Cycle 7 Day 1,Cycle 12 Day 1,Cycle 17 Day 1. each cycle is 28 days.

  12. Peak concentration (Cmax), arm 3 and 4

    The maximum serum concentration after administration in arm 3 and 4.

    Time frame: Pre-dose, 30 minuets after dose of Cycle 1 Day 1,Cycle 2 Day 1, Cycle 4 Day 1,Cycle 7 Day 1,Cycle 12 Day 1,Cycle 17 Day 1. each cycle is 21 days.

07

Study locations

2 of 2 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2023 (actual). Primary completion is estimated for Dec 2026, 44 months after the start.

Of 163 industry-sponsored phase 1/2 interventional studies under Breast Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 75. This study's planned 44 months is below that.

Counting every sponsor, half of 330 studies reached it within 62 months; a quarter within 45 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 2, 2024
First posted
Jan 11, 2024
StartActual
Apr 13, 2023
Primary completionEst.
Dec 2026
CompletionEst.
Oct 2027
Last update
Mar 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06202261
Responsible party
Sponsor
First posted
Jan 11, 2024
Start date
Apr 13, 2023
Primary completion
Dec 2026 (estimated)
Completion
Oct 2027 (estimated)
Last update
Mar 12, 2024

Study contacts

Qingyuan Zhang, Doctor
Contact
sy86298276@163.com
+86 0451 86298070
Xiaohua Zeng, Doctor
Contact
zengxiaohua000017@163.com
13983687701

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-HER2 Bispecific Antibody TQB2930

Start the discussion